Please login to the form below

Not currently logged in
Email:
Password:

CHMP recommends 19 new medicines for European approval

Praxbind and Entresto - both fast-tracked - among those to be backed
CHMP

European regulatory advisors at the CHMP backed 19 new medicines for approval last week at the Committee's busiest meeting so far this year.

The Committee for Medicinal Products for Human Use (CHMP) recommended Boehringer Ingelheim's Praxbind (idarucizumab) and Novartis' Entresto (sacubitril/valsartan), both of which have also been fast-tracked under the accelerated assessment procedure.

Praxbind is a reversal agent for Boehringer's Pradaxa (dabigatran) and could give the company a significant boost in the highly competitive market for novel oral anticoagulants.

Novartis' potential blockbuster Entresto is a treatment for symptomatic chronic heart failure with reduced ejection fraction that received early approval in the US over the summer. 

The CHMP also granted Amgen two positive opinions for its myeloma drug Kyprolis and leukaemia drug Blincyto, and recommended Exelis' metastic melanoma drug Cotellic (cobimetinib).

AstraZeneca too scored a double recommendation in type 2 diabetes, with Edistride (dapagliflozin) and Ebymect (dapagliflozin/metformin) backed by the CHMP.

Also recommended were Gilead's Genvoya (elvitegravir/cobicstat/emitricitabine/tenofovir alafenamide), which treats HIV infection, and GlaxoSmithKline's asthma drug Nucala (mpeolizumab).

Vertex Pharmaceuticals' Orkambi (lumacaftor/ivacaftor), a combination treatment for cystic fibrosis, also received a thumbs up, as did Impax's Parkinson's disease treatment Numient (levodopa/carbidopa).

Rounding out the list of branded medicines set for European approval were Incline Thereapeutics' Ionsys (fentanyl) for treating post-operative pain and two orphan drugs: Sobi's haemophilia A treatment Elocta and Horizon Therapeutics' Ravicti (glycerol phenylbutyrate) which is used for urea cycle disorders.

Generic Approvals

Additionally five generic medicines were recommended by the CHMP, including Aripiprazole Accord (aripiprazole) - a version of Lundbeck's schizophrenia and bipolar disorder treatment Abilify.

The remaining four generics are Ciambra, Pemetrexed Hospira and Pemetrexed Medac - all versions of Lilly's mesothelioma and non-small cell lung cancer Alimta (pemetrexed) - and Cinacalet Mylan (cinacalet), a version of Amgen's hyperparathyroidism and parathyroid carcinoma drug Mimpara.

Article by
Nikhil Patel

30th September 2015

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Langland

Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...

Latest intelligence

The doctor will text you now: Why healthcare providers cannot underestimate the importance of communicating change
Healthcare communication needs to switch from ‘transmit’ to ‘receive’, listening to what patients need and embracing the plethora of communication tools wholeheartedly....
How to innovate and influence people in times of misinformation
The pandemic has shown that public trust in promising new medical technologies is far from a given. Senior Writer Tom Vandyck at StoneArch, a member of Fishawack delves into the...
Could femtech be the answer to the gender health gap?
Here, we discuss the phenomenon of femtech, an industry that puts women’s experiences of lifestyle and health front and centre. We highlight some of the major players in the industry,...